Published in J Neural Transm (Vienna) on April 20, 2016
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging (1995) 6.86
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
An improved approach to prepare human brains for research. J Neuropathol Exp Neurol (1995) 1.84
The genetics of Parkinson disease. J Geriatr Psychiatry Neurol (2010) 1.69
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet (2006) 1.47
Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol (2011) 1.23
Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus. Neurobiol Aging (2007) 1.18
An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J Neurol Neurosurg Psychiatry (2012) 1.09
Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. Alzheimers Res Ther (2014) 1.06
The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol (2012) 1.05
Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res (1999) 1.04
Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One (2011) 1.04
Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging (2013) 0.94
Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord (2013) 0.87
MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies. Neurobiol Aging (2012) 0.84
Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiol Aging (2014) 0.84
Clinical subtypes in Parkinson's disease: the impact of MAPT haplotypes. J Neural Transm (Vienna) (2013) 0.79
The microtubule associated protein tau H1 haplotype and risk of essential tremor. Eur J Neurol (2013) 0.77